mRNA-3927
- Generic Name
- mRNA-3927
- Drug Type
- Biotech
Overview
mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid nanoparticle (LNP). Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.
Background
mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid nanoparticle (LNP). Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.